Informations générales (source: ClinicalTrials.gov)
French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T)
Observational [Patient Registry]
The Lymphoma Academic Research Organisation (Voir sur ClinicalTrials)
décembre 2019
décembre 2038
05 avril 2025
This study is a registry including prospective and retrospective data on all patients who
have been presented in a Multidisciplinary tumor board or RCP to be eligible for CAR-T
cell treatment.
Etablissements
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| AP-HP - Hôpital Cochin | Jérémie ZERBIT, Dr | Contact (sur clinicalTrials) | |||
| AP-HP - Hôpital Necker-Enfants Malades | Olivier HERMINE, Pr | Contact (sur clinicalTrials) | |||
| AP-HP - Hôpital Saint Antoine | Mohamad MOHTY, Pr | Contact (sur clinicalTrials) | |||
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Centre Francois Magendie - Pessac - France | Kamal BOUABDALLAH, MD | Contact (sur clinicalTrials) | |||
| Centre Henri Becquerel - Rouen - France | Fabrice JARDIN, Pr | Contact (sur clinicalTrials) | |||
| Centre Hospitalier Lyon Sud - Pierre Bénite - France | Emmanuel BACHY, Pr | Contact (sur clinicalTrials) | |||
| CHRU Besançon - Hôpital Minjoz - Besançon - France | Adrien CHAUCHET, MD | Contact (sur clinicalTrials) | |||
| CHU de Dijon - Dijon - France | Olivier CASASNOVAS, MD | Contact (sur clinicalTrials) | |||
| CHU de Nantes - Hôtel Dieu - Nantes - France | Thomas GASTINNE, MD | Contact (sur clinicalTrials) | |||
| CHU de Nice - Nice - France | Michaël LOSCHI, MD | Contact (sur clinicalTrials) | |||
| CHU de Rennes - Hôpital Pontchaillou - Rennes - France | Thierry LAMY-DE-LA-CHAPELLE, Pr | Contact (sur clinicalTrials) | |||
| CHU d'Estaing - Clermont-Ferrand - France | Jacques-Olivier BAY, Pr | Contact (sur clinicalTrials) | |||
| Institut Universitaire du Cancer - Oncopole Toulouse (IUCT-O) - Toulouse - France | Pierre BORIES, MD | Contact (sur clinicalTrials) | |||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| APHP - Hôpital Henri Mondor - Créteil - France | Fabien LE BRAS, MD | Contact (sur clinicalTrials) | |||
| APHP - Hôpital La Pitié Salpêtrière - Paris - France | Sylvain CHOQUET, MD | Contact (sur clinicalTrials) | |||
| APHP - Hôpital Saint Louis - Paris - France | Catherine THIEBLEMONT, Pr | Contact (sur clinicalTrials) | |||
| APHP - Hôpital Universitaire Robert Debré - Paris - France | André BARUCHEL, Pr | Contact (sur clinicalTrials) | |||
| Centre Léon Bérard - Lyon - France | Contact (sur clinicalTrials) | ||||
| CHRU de Lille - Hôpital Claude Hurriez - Lille - France | Ibrahim YAKOUB-AGHA, Pr | Contact (sur clinicalTrials) | |||
| CHU Angers - Angers - France | Aline TANGUY-SCHMIDT, MD | Contact (sur clinicalTrials) | |||
| CHU Brabois - Vandoeuvre les Nancy - France | Marie-Thérèse RUBIO, Pr | Contact (sur clinicalTrials) | |||
| CHU Bretonneau - Tours - France | Emmanuel GYAN, MD | Contact (sur clinicalTrials) | |||
| CHU d'Amiens - Hôpital Sud - Amiens - France | Magalie JORIS, MD | Contact (sur clinicalTrials) | |||
| CHU de Brest - Hôpital du Morvan - Brest - France | Adrian TEMPESCUL, MD | Contact (sur clinicalTrials) | |||
| CHU de Grenoble - La Tronche - France | Sylvain CARRAS, MD | Contact (sur clinicalTrials) | |||
| CHU de Montpellier - Montpellier - France | Guillaume CARTRON, Pr | Contact (sur clinicalTrials) | |||
| CHU de Rouen Normandie - Rouen - France | Nimrod BUCHBINDER, MD | Contact (sur clinicalTrials) | |||
| Gustave Roussy Cancer Campus - Villejuif - France | Cristina CASTILLA LLORENTE, MD | Contact (sur clinicalTrials) | |||
| Hôpital de la Milétrie - CHU de Poitiers - Poitiers - France | Xavier LELEU, Pr | Contact (sur clinicalTrials) | |||
| Hôpital de la Timone - Marseille - France | Arthur STERIN, MD | Contact (sur clinicalTrials) | |||
| Hôpital Dupuytren - Limoges - France | Julie ABRAHAM, MD | Contact (sur clinicalTrials) | |||
| ICANS (Institut de Cancérologie Strasbourg Europe) - Strasbourg - France | Blandine GUFFROY, MD | Contact (sur clinicalTrials) | |||
| Institut de Cancérologie Hématologie Universitaire de Saint Etienne - Saint-Priest-en-Jarez - France | Ludovic FOUILLET, MD | Contact (sur clinicalTrials) | |||
| Institut d'Hématologie de Basse Normandie - Caen - France | Ghandi DAMAJ, Pr | Contact (sur clinicalTrials) | |||
| Institut d'Hématologie et d'Oncologie Pédiatrique (IHOP) - Lyon - France | Yves BERTRAND, Pr | Contact (sur clinicalTrials) | |||
| Institut Paoli Calmette - Marseille - France | Aude Collignon, MD | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
Retrospective inclusion :
- Patient treated with CAR-T from 1 July 2018 under temporary authorization (ATU) or
covered by French health insurance system (under post-ATU or MA) in a qualified
center before activation of this register in this center
- If the patient is alive, the patient has been informed of the collection and use of
their data, and the patient has not opposed this use. If the patient has died, the
patient did not opposed the use of their data while alive
Prospective inclusion :
- Patient eligible for a treatment with CAR-T for an hematological malignancy which is
covered by French health insurance (for ATUs / post-ATUs or MA), or as part of a
clinical trial with the same indication, after the activation of this register in
this center.
- Patient whose CAR-T indication has been validated during a multidisciplinary tumor
board (RCP) of a qualified center, according to the ministerial order of 8 August
2019
- Patient deemed eligible for a treatment with CAR-T after a medical exam performed in
a qualified center according to the ministerial order of 8 August 2019
- If the patient is alive, the patient has been informed of the collection and use of
their data, and the patient has not opposed this use. If the patient has died, the
patient did not opposed the use of their data while alive.
Exclusion Criteria Patient not registered with the social security in France
Retrospective inclusion :
- Patient treated with CAR-T from 1 July 2018 under temporary authorization (ATU) or
covered by French health insurance system (under post-ATU or MA) in a qualified
center before activation of this register in this center
- If the patient is alive, the patient has been informed of the collection and use of
their data, and the patient has not opposed this use. If the patient has died, the
patient did not opposed the use of their data while alive
Prospective inclusion :
- Patient eligible for a treatment with CAR-T for an hematological malignancy which is
covered by French health insurance (for ATUs / post-ATUs or MA), or as part of a
clinical trial with the same indication, after the activation of this register in
this center.
- Patient whose CAR-T indication has been validated during a multidisciplinary tumor
board (RCP) of a qualified center, according to the ministerial order of 8 August
2019
- Patient deemed eligible for a treatment with CAR-T after a medical exam performed in
a qualified center according to the ministerial order of 8 August 2019
- If the patient is alive, the patient has been informed of the collection and use of
their data, and the patient has not opposed this use. If the patient has died, the
patient did not opposed the use of their data while alive.
Exclusion Criteria Patient not registered with the social security in France